Not sure where to start? Get matched →
All of Semaglutide (Injectable)
Semaglutide (Injectable) in West Virginia
Popular
West Virginia

Semaglutide (Injectable) in West Virginia

Doctor-prescribed Semaglutide (Injectable) for West Virginia residents. Reviewed by licensed West Virginia physicians, compounded at FDA-registered pharmacies, and shipped to your door.

All-in monthly price

$99

No membership fee · this is the full price · free shipping · avg 4-week supply

Medication, provider care, labs & dose adjustments — all in one price.
~28-day supply. Your provider sets your exact dose, so yours may vary — your refill arrives as you finish the last one.
Start assessment

Add in-depth bloodwork

Optional — add a physician-reviewed at-home blood panel to your plan.

At-home kit (1 device)+$149

Your sex-hormone baseline plus the safety markers that matter on therapy — blood counts, liver and kidney function — from one painless upper-arm device. Matched to your sex (PSA for men; progesterone & FSH for women). No needle, no clinic, physician-reviewed.

Money-back guarantee
Free AI care assistant
HSA/FSA accepted
Cancel anytime
Free shipping

This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.

Dr. Gene
Physician Reviewed

Reviewed by Dr. Gene, MD · Board-certified Family Medicine

Every Pepti prescription is reviewed by a licensed U.S. physician before it's dispensed — and only provided if clinically appropriate.

The process

How it works in West Virginia

  1. 1Complete a free online intake (~5 minutes).
  2. 2A licensed West Virginia physician reviews your case within 24 hours.
  3. 3Your prescription ships from our FDA-registered compounding pharmacy.
  4. 4Free shipping arrives 2–4 business days later. Refills ship automatically when your supply runs out — cancel anytime.
The treatment

What Semaglutide (Injectable) does

GLP-1 receptor agonist prescribed for medical weight management under licensed physician supervision. Compounded; not FDA-approved.

✓Appetite control
✓Significant weight loss
✓Blood sugar support
✓Cardiovascular health
Formulation
Injectable vial1 to 3 mL, sized to your dose
Semaglutidecompounded to your dose

Strength is compounded to the exact dose your physician prescribes and stepped up over time; paired with B6 to ease nausea.

Amounts shown are per unit. Compounded fresh at a US FDA-registered pharmacy.

Quality

Every batch independently tested

Every medication batch dispensed through Pepti is independently tested by a qualified third-party laboratory for applicable quality and safety standards before the pharmacy releases it. Batches are tested to the same standard used by 503B outsourcing facilities.

Sterility

USP <71>

Confirms the finished preparation is free of viable microorganisms.

Bacterial endotoxins

USP <85>

Screens for endotoxins that can cause fever or inflammatory reactions.

Potency

Assay

Verifies the labeled concentration of the active peptide is what is in the vial.

Purity

HPLC

Checks the active peptide against impurities and degradation products.

Identity

Mass spectrometry

Confirms the peptide in the vial is the correct molecule.

pH

USP <791>

Confirms the solution sits within the range specified for injection.

Particulate matter

USP <788>

Checks the finished vial for visible and sub-visible particles.

Container closure integrity

USP <1207>

Confirms the vial seal holds so sterility is maintained through the beyond-use date.

Recent lots

  • Lot 100526-SEM-1

    Tested 2026-10-07 · Biolink Life Sciences Carolinas

    Sterility

    Sterile

    Endotoxin

    <2 EU/mL

    Potency

    99.2%

  • Lot 100526-SEM-2

    Tested 2026-10-07 · Biolink Life Sciences Carolinas

    Sterility

    Sterile

    Endotoxin

    <2 EU/mL

    Potency

    98.7%

  • Lot 100526-SEM-2.5

    Tested 2026-10-07 · Biolink Life Sciences Carolinas

    Sterility

    Sterile

    Endotoxin

    <2 EU/mL

    Potency

    99.2%

Compounded by licensed U.S. pharmacies. Prescribed by licensed medical providers. Shipped directly to patients in West Virginia.Documentation available upon request →View lab results by lot →
West Virginia

Telemedicine in West Virginia.

West Virginia permits telemedicine prescribing under the West Virginia Telemedicine Act and Board of Medicine rules. A West Virginia-licensed physician can establish the patient relationship through online intake review. Pepti is available in all 50 states and Washington, D.C.

West Virginia has the highest adult obesity rate in the country, driving strong demand for GLP-1 and metabolic peptide therapy delivered via telehealth.

West Virginia cities Pepti serves

Pepti delivers Semaglutide (Injectable) to patients across West Virginia, including Charleston, Huntington, Morgantown, Parkersburg, Wheeling. All shipments use the same FDA-registered compounding pharmacy regardless of city.

Weight management in West Virginia

The CDC reports 40%+ (CDC 2023) adult obesity prevalence in West Virginia, well above the threshold where GLP-1 therapy demonstrates significant clinical benefit. Semaglutide (Injectable) is prescribed in West Virginia when BMI thresholds and intake criteria are met under physician review.

Your protocol

How Semaglutide is prescribed in West Virginia.

Who it's for

  • Adults with a BMI in the range their physician considers appropriate for GLP-1 therapy
  • Patients who have struggled with appetite and weight despite diet and exercise
  • People who want physician-managed dose escalation rather than a fixed dose
  • Patients already on semaglutide who want to continue at their current dose

Your physician decides whether Semaglutide is appropriate for you after reviewing your intake and labs.

Directions & duration

Inject 0.25 mL (25 units) subcutaneously once weekly.

Cycle. Weekly injection. New to it? Dose steps up on a schedule set by your physician; you can request the next step when you're ready. Already on it? Choose your current dose when you order and your physician confirms it at review. Pricing is by dose.
Ready for more? When you're ready, ask your physician to step up to the next dose. Approved steps are charged at the price difference and applied to your next fill.
Directions shown are the pharmacy's standard for this preparation. Your prescription label is the final word.

What's included

  • Licensed physician review of your intake, history, and labs
  • Medication compounded to your prescription by a PCAB-accredited, FDA-registered pharmacy
  • Every batch independently tested before release
  • Sterile syringes and alcohol prep pads for injectables
  • Tracked delivery to your door, refills on schedule
  • Message your physician anytime; dose changes without an appointment

Storage & handling

  • Store refrigerated (36–46°F / 2–8°C) at all times, including before first use.
  • One vial is your monthly supply. A fresh vial ships to your West Virginia address every 28 days on your refill schedule, so you're always well inside the beyond-use date on your label.
  • Protect from light. Wipe the stopper with an alcohol pad before every draw.
  • Dispose of syringes in the sharps container per the included instructions.

What to expect

A typical course of Semaglutide in West Virginia.

TimeframeWhat patients commonly report
Weeks 1–4Reduced appetite and earlier fullness are the most common first changes. Mild nausea is common while the body adjusts; for patients new to the medication the starting dose is deliberately low. Already on it? Your provider can continue you at the dose you're on.
Weeks 5–12As the dose steps up under physician direction, weight change typically becomes measurable. Slower is safer.
Month 3 onwardOngoing physician monitoring; long-term results in studies depended on continued treatment alongside diet and activity.
Individual results vary. Compounded medications are not FDA-approved; a licensed physician determines whether treatment is appropriate and monitors your progress.

The science

How Semaglutide works, and what the research shows.

How it works

Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone.

It slows gastric emptying, reduces appetite at the hypothalamic level, and improves insulin sensitivity.

Clinical trials show 15-20% body weight loss over 68 weeks.

Clinical evidence

  • The landmark STEP 1 trial randomized 1,961 adults with obesity to weekly subcutaneous semaglutide 2.4 mg vs placebo.

    Wilding et al., NEJM 2021
  • After 68 weeks, the semaglutide arm achieved a mean weight loss of 14.9% of body weight compared to 2.4% on placebo.

  • The SUSTAIN program demonstrated significant HbA1c reduction in type 2 diabetes, and the SELECT trial extended the evidence to cardiovascular outcomes — semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease.

    2023
  • Compounded semaglutide uses the identical active pharmaceutical ingredient prepared by FDA-registered 503A pharmacies.

Full references with PubMed links are listed further down the page.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine (2021) · PMID 33567185
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) · New England Journal of Medicine (2023) · PMID 37952131
  3. Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3) · JAMA (2021) · PMID 33625476
  4. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial · JAMA (2021) · PMID 33755728
  5. Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine (2016) · PMID 27633186
  6. Davies M, Færch L, Jeppesen OK, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial · The Lancet (2021) · PMID 33667417
  7. Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial · Nature Medicine (2022) · PMID 36216945
  8. Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial · JAMA (2022) · PMID 35015037
  9. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) · New England Journal of Medicine (2025) · PMID 40353578
  10. Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) · New England Journal of Medicine (2025) · PMID 40305708
  11. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension · Diabetes Obes Metab (2022) · PMID 35441470
  12. Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR et al.. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review · Ann Intern Med (2026) · PMID 41996180
  13. Pasternak B, Wintzell V, Hviid A et al.. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study · BMJ (2024) · PMID 38683947
  14. Bezin J, Gouverneur A, Pénichon M et al.. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer · Diabetes Care (2023) · PMID 36356111
  15. Hendershot CS, Bremmer MP, Paladino MB, et al.. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial · JAMA Psychiatry (2025) · PMID 39937469
  16. Klausen MK, Jensen ME, Møller M, et al.. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial · JCI Insight (2022) · PMID 36066977
  17. Quddos F, Hubshman Z, Tegge A, et al.. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity · Scientific Reports (2023) · PMID 38017205
  18. Wang W, Volkow ND, Berger NA, et al.. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population · Nature Communications (2024) · PMID 38806481
  19. Lähteenvuo M, Tiihonen J, Solismaa A, et al.. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder · JAMA Psychiatry (2025) · PMID 39535805
  20. Eshraghi R, Ghadimi DJ, Montazerinamin S, et al.. Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis · EClinicalMedicine (2025) · PMID 41324012
  21. de Faria Moraes B, André Pedral Diniz Leite G, Silveira IB, et al.. Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis · Drug and Alcohol Dependence (2025) · PMID 40845737
  22. Jensen ME, Klausen MK, Bergmann ML, et al.. Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption · Alcohol, Clinical and Experimental Research (2025) · PMID 40123107
  23. Hjerpsted JB, Flint A, Brooks A, et al.. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity · Diabetes, Obesity and Metabolism (2018) · PMID 28941314
  24. Jensterle M, Ferjan S, Ležaič L, et al.. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity · Diabetes, Obesity and Metabolism (2023) · PMID 36511825
  25. Dahl K, Brooks A, Almazedi F, et al.. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes · Diabetes, Obesity and Metabolism (2021) · PMID 33710717
  26. Wu KL, Chaikomin R, Doran S, et al.. Artificially sweetened versus regular mixers increase gastric emptying and alcohol absorption · The American Journal of Medicine (2006) · PMID 16945619
  27. Mitchell MC Jr, Teigen EL, Ramchandani VA. Absorption and peak blood alcohol concentration after drinking beer, wine, or spirits · Alcoholism: Clinical and Experimental Research (2014) · PMID 24655007
  28. Edelbroek MA, Horowitz M, Wishart JM, et al.. Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects · Journal of Nuclear Medicine (1993) · PMID 8455074
  29. Samokhvalov AV, Rehm J, Roerecke M. Alcohol Consumption as a Risk Factor for Acute and Chronic Pancreatitis: A Systematic Review and a Series of Meta-analyses · EBioMedicine (2015) · PMID 26844279
  30. Legro RS, Dodson WC, Kris-Etherton PM, et al.. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome · J Clin Endocrinol Metab (2015) · PMID 26401593
  31. Chen H, Lei X, Yang Z, et al.. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial · Reprod Biol Endocrinol (2025) · PMID 40713699
  32. Huang KP, Acosta AA, Ghidewon MY, et al.. Dissociable hindbrain GLP1R circuits for satiety and aversion · Nature (2024) · PMID 38987598
  33. Kanoski SE, Rupprecht LE, Fortin SM, et al.. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide · Neuropharmacology (2012) · PMID 22227019
  34. Orsama AL, Mattila E, Ermes M, van Gils M et al.. Weight rhythms: weight increases during weekends and decreases during weekdays · Obes Facts (2014) · PMID 24504358
  35. Steinberg DM, Bennett GG, Askew S, Tate DF. Weighing every day matters: daily weighing improves weight loss and adoption of weight control behaviors · J Acad Nutr Diet (2015) · PMID 25683820
  36. Ross R, Neeland IJ, Yamashita S, Shai I et al.. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity · Nat Rev Endocrinol (2020) · PMID 32020062
  37. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity · Diabetes Obes Metab (2021) · PMID 33269530
  38. Tronieri JS, Allison KC, DeRouen K, et al.. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial · American Journal of Clinical Nutrition (2026) · PMID 42323166
  39. Frid AH, Kreugel G, Grassi G, Halimi S, et al.. New Insulin Delivery Recommendations · Mayo Clin Proc (2016) · PMID 27594187
  40. Wang K, Zhang S, Liu C, Chen Y. A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy · Therapie (2021) · PMID 33958198
  41. Chen L, Xing Q, Li J, Zhou J. Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial · Diabetes Ther (2021) · PMID 33570716
  42. Malgave A, Akbar S, Joseph A, Dande Aishwarya, Peraman R, Malayandi R. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery · Eur J Pharm Biopharm (2025) · PMID 40490042
  43. Akbar S, Malgave A, Joseph A, Kumar A, Malayandi R. Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation · Pharm Res (2026) · PMID 42086873
  44. Benet A, Halseth T, Kang J, Kim A, Ackermann R, Srinivasan S, Schwendeman S, Schwendeman A. The Effects of pH and Excipients on Exenatide Stability in Solution · Pharmaceutics (2021) · PMID 34452224
  45. Kopp KL, Lamberth K, Schelde O, et al.. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists · Pharmaceutical Research (2026) · PMID 42533250
  46. Belcourt J, Sapowadia A, White CM, et al.. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown · The Annals of Pharmacotherapy (2026) · PMID 41689811
  47. Mohan V, Kalra S, Ahluwalia A, et al.. Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications · Cureus (2026) · PMID 42769283
  48. Perkovic V, Tuttle KR, Rossing P, et al.. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) · New England Journal of Medicine (2024) · PMID 38785209
  49. Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide · JAMA Ophthalmology (2024) · PMID 38958939
  50. He L, Wang J, Ping F, et al.. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials · JAMA Internal Medicine (2022) · PMID 35344001
  51. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M.. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss · JAMA (2023) · PMID 37796527
  52. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R.. Association of semaglutide with risk of suicidal ideation in a real-world cohort · Nature Medicine (2024) · PMID 38182782
  53. Guo L, Klonoff DC, Al Sifri SN, Bee YM et al.. Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts · Diabetes Research and Clinical Practice (2026) · PMID 42398590
  54. Plutzky J, Bogdański P, Colhoun HM et al.. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis · Circulation (2026) · PMID 42610271
  55. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel · J Clin Pharmacol (2015) · PMID 25475122
  56. Lau J, Bloch P, Schäffer L, et al.. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide · Journal of Medicinal Chemistry (2015) · PMID 26308095
  57. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide · Frontiers in Endocrinology (2019) · PMID 31031702
  58. Wharton S, Calanna S, Davies M, et al.. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss · Diabetes, Obesity and Metabolism (2022) · PMID 34514682
  59. Wharton S, et al.. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial · The Lancet Diabetes & Endocrinology (2025) · PMID 40961952
  60. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery · Nat Rev Drug Discov (2021) · PMID 33536635
  61. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions · Bioorg Med Chem (2018) · PMID 28720325
  62. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions · Drug Discov Today (2015) · PMID 25450771
  63. Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review · Drug Des Devel Ther (2024) · PMID 38952487
  64. Barenbaum SR, Kumar RB, Aronne LJ. Management of Medication-Induced Weight Gain · Gastroenterology Clinics of North America (2023) · PMID 37919025
  65. Kumar RB, Aronne LJ. Iatrogenic Obesity · Endocrinology and Metabolism Clinics of North America (2020) · PMID 32418589
  66. Biondi B. Subclinical Hypothyroidism in Patients with Obesity and Metabolic Syndrome: A Narrative Review · Nutrients (2023) · PMID 38201918
  67. Murphy C, Koehler K. Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression · Scandinavian Journal of Medicine and Science in Sports (2022) · PMID 34623696

Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.

Pharmacy network accreditation

PCAB-accredited pharmacies on every order.

Every fulfillment runs through a PCAB-accredited pharmacy.

See the lab results
PCAB — Pharmacy Compounding Accreditation Board · Accredited
  • Rigorous third-party quality & safety inspections
  • Cleanliness and sterile processes
  • Proper ingredient sourcing
  • Accurate dosing and formulation
  • Staff training and procedures
  • Accredited by NABP & ACHC
Common questions

Frequently asked
about Semaglutide (Injectable) in West Virginia.

Yes. Semaglutide (Injectable) is legal when prescribed by a physician licensed in West Virginia and dispensed by an FDA-registered compounding pharmacy. West Virginia permits telemedicine prescribing under the West Virginia Telemedicine Act and Board of Medicine rules. A West Virginia-licensed physician can establish the patient relationship through online intake review.

33 more questions about Pepti, answered.

Pepti serves all of West Virginia. A physician licensed in West Virginia reviews every order within 4 hours, the prescription is compounded by a state-licensed, FDA-registered pharmacy, and it ships free and tracked to any West Virginia street address. The price is the same as every other state.

Pepti operates in West Virginia through licensed physician partnerships. Compounded medications are produced at FDA-registered 503A pharmacies. Treatment decisions are made by your prescribing physician.